Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
AZN
$94.65
$0.64
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Next Earnings
2026-01-11
Beta
0.193
Average Volume
4936487
Market Cap
293468667875
Last Dividend
1.565
CIK
0000901832
ISIN
US0463531089
CUSIP
046353108
CEO
Pascal Claude Roland Soriot
Sector
Healthcare
Industry
Drug Manufacturers - General
Full Time Employees
94300
IPO Date
1993-05-12
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| AstraZeneca: Oncology Dominance Justifies New All-Time Highs | AstraZeneca started 2026 on a high note. On January 7, its stock reached an all-time high of $95.94. The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. | Seeking Alpha | 2026-01-10 10:00:00 |
| Healthcare Dividend Stocks: The Recession-Proof Income Play for 2026 | If a recession were to hit, it's a foregone conclusion that people won't stop taking their prescriptions, and they won't cancel major medical treatments. | 24/7 Wall Street | 2026-01-10 09:41:12 |
| D.A. Davidson & CO. Has $2.34 Million Holdings in AstraZeneca PLC $AZN | D.A. Davidson and CO. lessened its stake in shares of AstraZeneca PLC (NASDAQ: AZN) by 18.0% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,474 shares of the company's stock after selling 6,689 shares during the quarter. D.A. Davidson and | Defense World | 2026-01-10 03:52:52 |
| Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know | Astrazeneca (AZN) concluded the recent trading session at $94.01, signifying a -1.21% move from its prior day's close. | Zacks Investment Research | 2026-01-08 19:16:16 |
| Here's Why Astrazeneca (AZN) is a Strong Momentum Stock | The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. | Zacks Investment Research | 2026-01-08 10:51:17 |
| AstraZeneca names Rick Suarez head of US biopharmaceuticals unit | AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the drugmaker's previously announced $50 billion research, development and manufacturing investment in the country. | Reuters | 2026-01-08 07:12:50 |
| Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit | WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the Company's previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca's largest single manufacturing investment globally. The investment underpins AstraZeneca's goal of generating $80. | Business Wire | 2026-01-08 07:00:00 |
| JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors? | J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion. | Zacks Investment Research | 2026-01-06 12:55:23 |
| Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? | Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. | Zacks Investment Research | 2026-01-06 10:45:33 |
| JP Morgan expects solid AstraZeneca quarter and reassuring outlook | AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is set to deliver a solid finish to 2025 when it reports fourth-quarter results next month, according to JP Morgan, which expects earnings to come in modestly ahead of market expectations and guidance for 2026 to underpin confidence in the growth outlook. The US bank forecasts fourth-quarter revenues of $15.5 billion, representing 2% growth at constant exchange rates and about 1% ahead of consensus forecasts. | Proactive Investors | 2026-01-06 08:13:41 |
| JP Morgan expects solid AstraZeneca quarter and reassuring outlook | AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is set to deliver a solid finish to 2025 when it reports fourth-quarter results next month, according to JP Morgan,... | Proactive Investors - Finance | 2026-01-06 07:46:00 |
| BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development | WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology drug development using BostonGene's multimodal AI platform. The collaboration leverages BostonGene's foun. | Business Wire | 2026-01-06 07:44:00 |
| LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026 | The festive period is, for some, a time for taking stock of what's happened in the past year - for others, though, its a time to pick stocks for the year ahead. So it is, then, that it's the season for looking ahead. | Proactive Investors | 2025-12-24 08:31:28 |
| ABBV vs. AZN: Which Pharma Stock is the Better Investment Now? | AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge. | Zacks Investment Research | 2025-12-23 11:56:10 |
| Here's Why Astrazeneca (AZN) is a Strong Value Stock | Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. | Zacks Investment Research | 2025-12-23 10:41:40 |
| 5 Big Drug Stocks That May Continue to Outperform in 2026 | Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026. | Zacks Investment Research | 2025-12-23 09:51:10 |
| AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised) | AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer. | Zacks Investment Research | 2025-12-23 04:16:05 |
| AstraZeneca (LON:AZN) Insider Nazneen Rahman Sells 297 Shares of Stock | AstraZeneca PLC (LON: AZN - Get Free Report) insider Nazneen Rahman sold 297 shares of the company's stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of £134.96, for a total value of £40,083.12. AstraZeneca Trading Down 0.5% Shares of AstraZeneca stock opened at £136.02 on Tuesday. The company's | Defense World | 2025-12-23 01:14:52 |
| AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use | AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal. | Zacks Investment Research | 2025-12-22 11:25:28 |
| Signal Advisors Wealth LLC Takes $473,000 Position in AstraZeneca PLC $AZN | Signal Advisors Wealth LLC bought a new position in shares of AstraZeneca PLC (NASDAQ: AZN) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 6,165 shares of the company's stock, valued at approximately $473,000. Other large investors have also recently bought and | Defense World | 2025-12-22 05:33:05 |
| AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial | The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer. | WSJ | 2025-12-22 02:39:00 |
| AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial | AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell lung cancer. | Reuters | 2025-12-22 02:22:11 |
| AstraZeneca (LON:AZN) Reaches New 12-Month High – Should You Buy? | Shares of AstraZeneca PLC (LON: AZN - Get Free Report) hit a new 52-week high during mid-day trading on Friday. The stock traded as high as £154.74 and last traded at £135.85, with a volume of 422522813 shares trading hands. The stock had previously closed at £135.48. Analyst Upgrades and Downgrades Several brokerages recently commented | Defense World | 2025-12-21 03:32:54 |
| AstraZeneca PLC $AZN Position Boosted by Benson Investment Management Company Inc. | Benson Investment Management Company Inc. raised its holdings in shares of AstraZeneca PLC (NASDAQ: AZN) by 18.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,297 shares of the company's stock after acquiring an additional 11,815 shares during the | Defense World | 2025-12-21 03:22:51 |
| This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter | CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research. | CNBC Television | 2025-12-19 18:25:01 |
| Trump to announce new drug-pricing deals later today | The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices. | Market Watch | 2025-12-19 10:45:00 |
| AstraZeneca: Mispriced Growth Following The Oncology Segment Success | AstraZeneca targets $80bn revenue by FY2030, driven by oncology leadership and robust pipeline execution. AZN demonstrates double-digit revenue and EBITDA growth, trading at a discount to high-growth peers despite comparable operating leverage. DCF suggests limited upside under conservative assumptions, but peer-based multiples indicate substantial appreciation potential, supporting a GARP investment case. | Seeking Alpha | 2025-12-19 02:30:33 |
| 3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now | These top healthcare companies all have strong underlying businesses. Their low valuations can make them attractive for bargain hunters. | The Motley Fool | 2025-12-18 20:30:00 |
| AstraZeneca PLC $AZN Shares Sold by Chesley Taft & Associates LLC | Chesley Taft and Associates LLC decreased its holdings in shares of AstraZeneca PLC (NASDAQ: AZN) by 4.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 126,765 shares of the company's stock after selling 5,670 shares during the period. Chesley Taft and | Defense World | 2025-12-18 04:42:56 |
| AstraZeneca Gets FDA Nod For Breast Cancer Drug, EU Clearance For Lupus Pen | FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo self-injection for lupus. | Benzinga | 2025-12-16 12:37:03 |
| AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer | AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer. | Zacks Investment Research | 2025-12-16 11:46:11 |
| Here's Why Astrazeneca (AZN) is a Strong Growth Stock | Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. | Zacks Investment Research | 2025-12-16 10:46:14 |
| First Look: Ford EV pivot, AI infra slump, Uber suit | Stock News Ford pivots from pure EVs, takes $19.5B charge: Ford Motor (F) will record about $19.5 billion in special items tied to a pullback from all-electric | GuruFocus | 2025-12-16 07:38:00 |
| AstraZeneca PLC (NASDAQ:AZN) Receives Consensus Recommendation of “Moderate Buy” from Analysts | Shares of AstraZeneca PLC (NASDAQ: AZN - Get Free Report) have been given an average rating of "Moderate Buy" by the nine ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 1-year target price | Defense World | 2025-12-16 03:54:47 |
| Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts | Astrazeneca (AZN) closed the most recent trading day at $91.56, moving +1.93% from the previous trading session. | Zacks Investment Research | 2025-12-15 19:16:06 |
| ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer | WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, as determined by a Food and Drug Administration (FDA)-approved test. The approval follows Priority Review and Breakthrough Therapy Designation by the FDA and is based on the results of the DESTINY-Breast09 Phase III trial. | Business Wire | 2025-12-15 16:29:00 |
| Geneos Wealth Management Inc. Grows Stock Holdings in AstraZeneca PLC $AZN | Geneos Wealth Management Inc. boosted its holdings in AstraZeneca PLC (NASDAQ: AZN) by 329.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 77,196 shares of the company's stock after buying an additional 59,228 shares during the quarter. Geneos Wealth Management Inc.'s | Defense World | 2025-12-15 04:09:02 |
| AstraZeneca (LON:AZN) Share Price Crosses Above 200-Day Moving Average – Should You Sell? | AstraZeneca PLC (LON: AZN - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of £117.76 and traded as high as £136.88. AstraZeneca shares last traded at £135.96, with a volume of 558,747,313 shares. Analyst Upgrades and Downgrades Several brokerages recently issued reports | Defense World | 2025-12-12 04:02:51 |
| AstraZeneca: A Rare Compound Growth Opportunity In Biopharma | AstraZeneca (AZN) offers a rare, secular growth profile in biopharma, underpinned by a diversified commercial asset base and layered patent expirations. AZN faces a minor patent cliff, with most key products' loss of exclusivity in the 2030s, and rapidly growing therapies offsetting near-term risks. The pipeline is robust and diversified, targeting 20 new molecular entities by 2030, supporting management's ambition to nearly double revenues to $80B. | Seeking Alpha | 2025-12-10 10:26:49 |
| BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 | Early data indicate that BI-1206 has the potential to reset one of the main resistance mechanisms to rituximab 47% of patients exhibited complete responses (CR), with an overall response rate of 80% Favorable safety profile with most (87%) adverse events being mild or moderate and no treatment-related discontinuations The safety run-in portion is complete with no apparent differences in safety or efficacy between the two dose levels; the signal-seeking expansion phase of the study is ongoing LUND, SE / ACCESS Newswire / December 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune‑modulatory antibodies for cancer immunotherapy, today announced the presentation of new data from the safety run-in portion of its ongoing trial evaluating BI-1206, an anti-FcγRIIB antibody, in combination with rituximab and Calquence® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Anti-CD20 antibodies like rituximab are essential for treating NHL. | Accesswire | 2025-12-08 08:10:00 |
| Leading bank tips AstraZeneca as 2026's standout UK pharma, with GSK left trailing | JPMorgan has put AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) at the top of its UK healthcare picks for 2026, arguing that the company enters the new year with one of the most catalyst-rich pipelines in global pharma. The bank says a wave of clinical readouts (and a high likelihood of success) positions AstraZeneca to benefit disproportionately as investors shift their attention away from US drug-pricing fears and back towards innovation. | Proactive Investors | 2025-12-08 07:33:23 |
| Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement | SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 CRM, today announced that AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company, has selected Agentforce Life Sciences for Customer Engagement to help transform its customer engagement globally, fostering stronger relationships with healthcare professionals (HCPs) through data-driven, AI-powered engagement. This work will support AstraZeneca's commitment to push the boundaries of science to deliv. | Business Wire | 2025-12-04 16:00:00 |
| AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH | WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6-9, 2025. This year's ASH congress will feature the Company's largest presence to date, with 65 abstracts across eight approved and investigational medicines, including 15 oral presentations. Key presentations include: Phase I trial of surovatamig: Updated r. | Business Wire | 2025-12-04 07:00:00 |
| 3 Potential Mid-Cap Biotech Buyout Targets In 2026 | The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for significant buyout premiums in recent months. | Seeking Alpha | 2025-12-03 18:22:57 |
| AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension | AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026. | Zacks Investment Research | 2025-12-03 11:05:20 |
| Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term | Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. | Zacks Investment Research | 2025-12-03 10:50:27 |
| Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension | WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pressure. The Prescription Drug User Fee Act (PDUFA) date is anticipated during the second quarter of 202. | Business Wire | 2025-12-02 09:18:00 |
| BREAKING: Trump strikes major deal with UK on drug pricing | FOX Business White House correspondent Edward Lawrence reports the details of President Donald Trump's pharmaceutical deal with the U.K. on 'Varney & Co.' | Fox Business | 2025-12-01 10:15:02 |
| Here's Why Astrazeneca (AZN) is a Strong Growth Stock | The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. | Zacks Investment Research | 2025-11-28 10:46:20 |
| AstraZeneca or Merck: Which Oncology Giant Has the Edge? | AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup. | Zacks Investment Research | 2025-11-27 10:46:25 |
| Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term | Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. | Zacks Investment Research | 2025-11-27 10:41:44 |
| Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies | The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from 2027, including Novo Nordisk's mega bestseller Ozempic which will see a 71% discount to its list price. | CNBC | 2025-11-26 12:18:29 |
| AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers | FDA approves AstraZeneca's Imfinzi plus FLOT for early gastric and GEJ cancers after Phase 3 data show strong event-free and overall survival benefits. | Benzinga | 2025-11-26 09:38:10 |
| Boston Partners Sells 46,721 Shares of AstraZeneca PLC $AZN | Boston Partners trimmed its stake in AstraZeneca PLC (NASDAQ: AZN) by 0.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,989,924 shares of the company's stock after selling 46,721 shares during the period. Boston Partners owned approximately 0.16% of | Defense World | 2025-11-26 05:14:43 |
| Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month | The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highest‑cost medications. | Benzinga | 2025-11-26 05:11:45 |
| Aviso Financial Inc. Has $2.95 Million Position in AstraZeneca PLC $AZN | Aviso Financial Inc. lifted its holdings in shares of AstraZeneca PLC (NASDAQ: AZN) by 5.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,228 shares of the company's stock after buying an additional 2,249 shares during the period. | Defense World | 2025-11-25 03:32:49 |
| AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows | Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ: AZN), initially established in March 2025. | Benzinga | 2025-11-24 12:58:16 |
| Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an update and advancement of its global strategic collaboration with AstraZeneca, originally established in March 2025. | PRNewsWire | 2025-11-23 19:01:00 |
| AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer | AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk manufacturing expansion, growth plans, next-gen therapies, and more. | CNBC Television | 2025-11-21 20:22:58 |
| Why AstraZeneca Stock Bumped Higher Today | The pharmaceutical giant is plowing billions of dollars into expanding its drug-making capacity. It has ambitious plans for two facilities in Maryland. | The Motley Fool | 2025-11-21 18:23:41 |
| AstraZeneca to invest $2 billion as part of US manufacturing push | AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabilities in the U.S. by 2030. | Reuters | 2025-11-21 14:05:51 |
| AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth | WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will support 2,600 jobs across the two sites in the state includin. | Business Wire | 2025-11-21 14:05:00 |
| AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo | AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN. | Zacks Investment Research | 2025-11-21 11:15:27 |
| AstraZeneca Wins FDA Nod For Koselugo In Adult NF1 | AstraZeneca's (AZN) Alexion unit scored an important milestone on Thursday, saying the FDA has approved Koselugo for adults with neurofibromatosis type 1 who ha | GuruFocus | 2025-11-20 13:57:00 |
| FTSE 100 Live: London and European stocks tumble, bitcoin sell-off deepens | 9.16am: European markets in selling mode After the first hour and a bit of trading, the Footsie is down 0.8%, which is one of the better performances among... | Proactive Investors - Finance | 2025-11-18 04:16:00 |
| Connor Clark & Lunn Investment Management Ltd. Lowers Holdings in AstraZeneca PLC $AZN | Connor Clark and Lunn Investment Management Ltd. lowered its stake in shares of AstraZeneca PLC (NASDAQ: AZN) by 34.1% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,495 shares of the company's stock after selling 10,587 | Defense World | 2025-11-17 04:36:59 |
| Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman | Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more. | CNBC Television | 2025-11-14 15:19:12 |
| Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes | Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in patients with diabetes, a study from India found. | Reuters | 2025-11-14 07:06:18 |
| Allianz SE Purchases 4,315 Shares of AstraZeneca PLC $AZN | Allianz SE raised its position in shares of AstraZeneca PLC (NASDAQ: AZN) by 148.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,219 shares of the company's stock after purchasing an additional 4,315 shares during the period. Allianz SE's holdings in | Defense World | 2025-11-14 04:03:09 |
| AstraZeneca leans on its pipeline as $80bn revenue target comes into view | It is not every day that a company makes a habit of turning in positive clinical results at a pace that would make even the most seasoned drug developer blink. Yet AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has managed just that this year, and Shore Capital thinks the torrent of data is enough to justify a fresh uplift to forecasts, even if the real strategic test lies a little further down the road. | Proactive Investors | 2025-11-13 07:49:58 |
| Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term | The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. | Zacks Investment Research | 2025-11-12 10:46:20 |
| FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines | London's export-focused FTSE 100 rose to a new intraday record peak on Tuesday, buoyed by a weakening pound after economic data revealed rising unemployment and slowing wage growth, while drugmaker AstraZeneca climbed to an all-time high. | Reuters | 2025-11-11 07:45:14 |
| AstraZeneca hits record high, cements lead as UK's biggest stock | Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's position as the largest UK-listed stock by market value. | Reuters | 2025-11-11 03:42:54 |
| Why AstraZeneca Stock Was a Winner Today | The pharmaceutical sector mainstay reported good news about its developmental hypertension drug. It purchased the medicine's maker, CinCor Pharma, in early 2023. | The Motley Fool | 2025-11-10 17:20:27 |
| AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial | AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well as safety and tolerability in participants with resistant hypertension. | Benzinga | 2025-11-10 13:39:23 |
| Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial | WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the 24-hour period, including early morning, when patients with. | Business Wire | 2025-11-09 16:33:00 |
| Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease | WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the NATRON Phase III trial showed AstraZeneca's FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in hypereosinophilic syndrome (HES),1 a rare disease driven by elevated eosinophils.2 These data will be presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida. Hypereosinophilic Syndrome (HES) is a group of. | Business Wire | 2025-11-07 09:00:00 |
| AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript | AstraZeneca PLC ( AZN ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Andrew Barnett - Head of Investor Relations Pascal Soriot - CEO & Executive Director Aradhana Sarin - CFO & Executive Director David Fredrickson - Executive Vice-President of Oncology Haematology Business Unit Susan Galbraith - Executive Vice President of Oncology R&D Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D Marc Dunoyer - CEO of Alexion & Chief Strategy Officer Conference Call Participants Michael Leuchten - Jefferies LLC, Research Division Sarita Kapila - Morgan Stanley, Research Division Justin Smith Sachin Jain - BofA Securities, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Peter Verdult - BNP Paribas, Research Division Mattias Häggblom - Handelsbanken Capital Markets AB, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Matthew Weston - UBS Investment Bank, Research Division Steve Scala - TD Cowen, Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division Gonzalo Artiach Castanon - Danske Bank A/S, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Presentation Operator Good afternoon, and welcome to AstraZeneca's 9 months and Q3 2025 webinar for investors and analysts. | Seeking Alpha | 2025-11-06 16:26:15 |
| AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade) | The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. AstraZeneca's financials remain robust, with double-digit revenue and EPS growth, but Q4 2025 is expected to show slower or even negative EPS growth. Risks could also stem from U.S. pricing pressures and potentially unresolved tax issues in China. Additionally, stretched valuations and limited near-term upside, prompt a Hold rating. | Seeking Alpha | 2025-11-06 15:28:24 |
| AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform | AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth. | Zacks Investment Research | 2025-11-06 12:45:31 |
| AstraZeneca climbs to net all-time high after US deal reassurance | AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted what analysts called a very solid set of third-quarter results, but the shares barely moved in early morning trading as the City waited for more details on the analyst call. In afternoon trading, shares in the giant drugmaker jumped over 4% to a new all time high above 12,990p. | Proactive Investors | 2025-11-06 11:21:36 |
| Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key Metrics | Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. | Zacks Investment Research | 2025-11-06 10:31:31 |
| AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar | AstraZeneca stock jumped Thursday after the drugmaker reported better-than-expected third-quarter sales and earnings. | Investors Business Daily | 2025-11-06 08:34:35 |
| AstraZeneca's 9M and Q3 2025 Financial Results | CAMBRIDGE, England--(BUSINESS WIRE)--Q3 2025 Results Release. | Business Wire | 2025-11-06 07:00:00 |
| AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO | AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration. | CNBC International TV | 2025-11-06 04:12:50 |
| AstraZeneca grows faster than expected but maintains guidance | AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted a confident set of third-quarter results, not only beating revenue and core earnings forecasts, but also hailing "strong underlying momentum" across the business to set up growth through next year as well. The FTSE 100 pharmaceutical group generated revenues of $15.19 billion in the three months to 30 September, up 12% compared to a year ago and beating the consensus forecast of $14.8 billion. | Proactive Investors | 2025-11-06 02:39:05 |
| AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal | The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to $15.19 billion from $13.57 billion. | WSJ | 2025-11-06 02:39:00 |
| AstraZeneca beats third-quarter revenue and profit expectations | AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting London's most valuable listed company to retain its full-year forecasts. | Reuters | 2025-11-06 02:04:56 |
| Breakthrough Properties voltooit One Helix, een geavanceerde onderzoeksfaciliteit die volledig aan AstraZeneca is verhuurd | /PRNewswire/ -- Breakthrough Properties, een toonaangevende wereldwijde ontwikkelaar van vastgoed ten behoeve van biowetenschappen, heeft vandaag de oplevering | PRNewsWire | 2025-11-05 18:40:00 |
| AstraZeneca wins shareholder backing for NYSE listing in US pivot | AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool. | Reuters | 2025-11-03 11:11:38 |
| AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US | AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool. | Reuters | 2025-11-03 11:06:23 |
| BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025 | LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will present new data from the safety run-in portion of its ongoing trial evaluating BI-1206 in combination with rituximab and Calquence ® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) in a poster at the upcoming 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Abstract data (as of August 4, 2025) published in the November supplemental issue of Blood demonstrates that the triple combination regimen is safe and well-tolerated, with encouraging efficacy data. | Accesswire | 2025-11-03 09:17:00 |
| Wall Street Week Ahead | Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. | Seeking Alpha | 2025-11-02 07:07:08 |
| AstraZeneca to face questions on Trump MFN deal, patent expiries and pipeline | When AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reports third-quarter results next Thursday, 6 November, with investors and analysts will be keen to hear about the financial implications of the 'most favoured nation' (MFN) pricing deal recently agreed with Donald Trump, as well as the loss of its Farxiga patent and prospects for new drugs coming out of its pipeline. This will be the first opportunity for discussion of the US MFN deal, making its a key discussion point, according to analysts at UBS. | Proactive Investors | 2025-10-31 11:39:53 |
| Short Interest in AstraZeneca PLC ADRhedged (BATS:AZNH) Increases By 200.0% | AstraZeneca PLC ADRhedged (BATS: AZNH - Get Free Report) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 300 shares, an increase of 200.0% from the September 30th total of 100 shares. Based on an average daily trading volume, of 5,300 | Defense World | 2025-10-31 01:48:44 |
| FTSE Index shares to watch next week: BT, BP, IAG, AstraZeneca, Marks & Spencer | The FTSE 100 Index has been in a strong bull run this year and is now trading at a record high of £9,760. It has jumped by 30% from its lowest point this year. | Invezz | 2025-10-31 01:19:33 |
| AstraZeneca PLC $AZN Stock Holdings Increased by Sumitomo Mitsui Trust Group Inc. | Sumitomo Mitsui Trust Group Inc. lifted its stake in AstraZeneca PLC (NASDAQ: AZN) by 15.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,315 shares of the company's stock after purchasing an additional 15,294 shares during the quarter. Sumitomo Mitsui | Defense World | 2025-10-30 04:53:01 |
| AstraZeneca PLC ADRhedged (BATS:AZNH) Short Interest Up 200.0% in October | AstraZeneca PLC ADRhedged (BATS: AZNH - Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 300 shares, an increase of 200.0% from the September 30th total of 100 shares. Based on an average daily trading volume, of 5,300 | Defense World | 2025-10-30 01:58:44 |
| Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors | Astrazeneca (AZN) closed at $82.61 in the latest trading session, marking a -1.72% move from the prior day. | Zacks Investment Research | 2025-10-28 19:16:10 |
| Pipeline power keeps AstraZeneca in rude health | AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is looking more marathon runner than sprinter these days. The pharmaceuticals giant has spent years building a pipeline that looked sprawling and costly. | Proactive Investors | 2025-10-27 06:53:54 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 6-K | 2026-01-08 | 2026-01-08 | View Filing |
| 6-K | 2026-01-02 | 2026-01-02 | View Filing |
| 6-K | 2025-12-22 | 2025-12-22 | View Filing |
| 6-K | 2025-12-22 | 2025-12-22 | View Filing |
| 6-K | 2025-12-22 | 2025-12-22 | View Filing |
| 6-K | 2025-12-19 | 2025-12-19 | View Filing |
| 6-K | 2025-12-16 | 2025-12-16 | View Filing |
| 6-K | 2025-12-16 | 2025-12-16 | View Filing |
| 6-K | 2025-12-04 | 2025-12-04 | View Filing |
| 6-K | 2025-12-01 | 2025-12-01 | View Filing |
| 6-K | 2025-12-01 | 2025-12-01 | View Filing |
| 6-K | 2025-11-26 | 2025-11-26 | View Filing |
| 6-K | 2025-11-20 | 2025-11-20 | View Filing |
| 6-K | 2025-11-17 | 2025-11-17 | View Filing |
| 25-NSE | 2025-11-14 | 2025-11-14 | View Filing |
| 6-K | 2025-11-14 | 2025-11-14 | View Filing |
| 6-K | 2025-11-10 | 2025-11-10 | View Filing |
| 6-K | 2025-11-06 | 2025-11-06 | View Filing |
| 6-K | 2025-11-03 | 2025-11-03 | View Filing |
| 6-K | 2025-11-03 | 2025-11-03 | View Filing |
| 6-K | 2025-11-03 | 2025-11-03 | View Filing |
| 6-K | 2025-10-28 | 2025-10-28 | View Filing |
| 6-K | 2025-10-28 | 2025-10-28 | View Filing |
| 6-K | 2025-10-22 | 2025-10-22 | View Filing |
| 6-K | 2025-10-20 | 2025-10-20 | View Filing |
| 6-K | 2025-10-20 | 2025-10-20 | View Filing |
| 6-K | 2025-10-14 | 2025-10-14 | View Filing |
| 6-K | 2025-10-07 | 2025-10-07 | View Filing |
| 6-K | 2025-10-06 | 2025-10-06 | View Filing |
| 6-K | 2025-10-01 | 2025-10-01 | View Filing |
| 6-K | 2025-09-29 | 2025-09-29 | View Filing |
| 6-K | 2025-09-29 | 2025-09-29 | View Filing |
| 6-K | 2025-09-29 | 2025-09-29 | View Filing |
| 6-K | 2025-09-25 | 2025-09-25 | View Filing |
| 6-K | 2025-09-22 | 2025-09-22 | View Filing |
| 6-K | 2025-09-22 | 2025-09-22 | View Filing |
| 6-K | 2025-09-17 | 2025-09-17 | View Filing |
| 6-K | 2025-09-17 | 2025-09-17 | View Filing |
| 6-K | 2025-09-02 | 2025-09-02 | View Filing |
| 6-K | 2025-08-28 | 2025-08-28 | View Filing |
| 6-K | 2025-08-26 | 2025-08-26 | View Filing |
| 6-K | 2025-08-21 | 2025-08-21 | View Filing |
| 6-K | 2025-08-18 | 2025-08-18 | View Filing |
| 6-K | 2025-08-15 | 2025-08-15 | View Filing |
| 6-K | 2025-08-12 | 2025-08-12 | View Filing |
| 6-K | 2025-08-01 | 2025-08-01 | View Filing |
| 6-K | 2025-07-29 | 2025-07-29 | View Filing |
| 6-K | 2025-07-24 | 2025-07-24 | View Filing |
| 6-K | 2025-07-22 | 2025-07-22 | View Filing |
| 6-K | 2025-07-16 | 2025-07-16 | View Filing |
| 6-K | 2025-07-14 | 2025-07-14 | View Filing |
| 6-K | 2025-07-07 | 2025-07-07 | View Filing |
| 6-K | 2025-07-01 | 2025-07-01 | View Filing |
| 11-K | 2025-06-26 | 2025-06-26 | View Filing |
| 6-K | 2025-06-24 | 2025-06-24 | View Filing |
| 6-K | 2025-06-13 | 2025-06-13 | View Filing |
| 6-K | 2025-06-12 | 2025-06-12 | View Filing |
| 6-K | 2025-06-06 | 2025-06-06 | View Filing |
| 6-K | 2025-06-02 | 2025-06-02 | View Filing |
| 6-K | 2025-06-02 | 2025-06-02 | View Filing |
| 6-K | 2025-05-27 | 2025-05-27 | View Filing |
| 6-K | 2025-05-23 | 2025-05-23 | View Filing |
| 6-K | 2025-05-21 | 2025-05-21 | View Filing |
| 6-K | 2025-05-20 | 2025-05-20 | View Filing |
| 6-K | 2025-05-09 | 2025-05-09 | View Filing |
| 6-K | 2025-05-07 | 2025-05-07 | View Filing |
| 6-K | 2025-05-06 | 2025-05-06 | View Filing |
| 6-K | 2025-05-02 | 2025-05-02 | View Filing |
| 6-K | 2025-05-01 | 2025-05-01 | View Filing |
| 6-K | 2025-05-01 | 2025-05-01 | View Filing |
| 6-K | 2025-04-29 | 2025-04-29 | View Filing |
| 6-K | 2025-04-29 | 2025-04-29 | View Filing |
| 6-K | 2025-04-29 | 2025-04-29 | View Filing |
| SC 13G/A | 2025-04-23 | 2025-04-23 | View Filing |
| 6-K | 2025-04-22 | 2025-04-22 | View Filing |
| 6-K | 2025-04-11 | 2025-04-11 | View Filing |
| SC 13G/A | 2025-04-10 | 2025-04-10 | View Filing |
| 6-K | 2025-04-04 | 2025-04-04 | View Filing |
| 6-K | 2025-04-04 | 2025-04-04 | View Filing |
| 6-K | 2025-04-01 | 2025-04-01 | View Filing |
| 6-K | 2025-03-31 | 2025-03-31 | View Filing |
| 6-K | 2025-03-31 | 2025-03-31 | View Filing |
| 6-K | 2025-03-21 | 2025-03-21 | View Filing |
| 6-K | 2025-03-17 | 2025-03-17 | View Filing |
| 6-K | 2025-03-17 | 2025-03-17 | View Filing |
| 6-K | 2025-03-17 | 2025-03-17 | View Filing |
| 6-K | 2025-03-12 | 2025-03-12 | View Filing |
| 6-K | 2025-03-07 | 2025-03-07 | View Filing |
| 6-K | 2025-03-07 | 2025-03-07 | View Filing |
| 6-K | 2025-03-07 | 2025-03-07 | View Filing |
| 6-K | 2025-03-07 | 2025-03-07 | View Filing |
| 6-K | 2025-03-06 | 2025-03-06 | View Filing |
| 6-K | 2025-03-05 | 2025-03-05 | View Filing |
| 6-K | 2025-03-03 | 2025-03-03 | View Filing |
| 6-K | 2025-03-03 | 2025-03-03 | View Filing |
| 6-K | 2025-02-28 | 2025-02-28 | View Filing |
| 6-K | 2025-02-26 | 2025-02-26 | View Filing |
| 6-K | 2025-02-19 | 2025-02-19 | View Filing |
| IRANNOTICE | 2025-02-18 | 2025-02-18 | View Filing |
| 20-F | 2025-02-18 | 2025-02-18 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Keltner Channel Strategy | 25.30% | 1.02 | 166 | 0.04 | 0.16 | 19.82 |
| Larry Williams PercentR Strategy | 25.01% | 1 | 341 | 0.04 | 0.16 | 19.53 |
| Williams PercentR Strategy | 22.69% | 1 | 576 | 0.03 | 0.14 | 17.21 |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | x | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |